Chronic Kidney Disease

  Healio spoke with Kevin Martin, MD, professor of medicine and director of the division of nephrology at Saint Louis University School of Medicine, about the challenges of managing hyperphosphatemia, prevention measures to recommend to patients at high risk for developing the condition, unmet needs in hyperphosphatemia management and more.

  Healio spoke with Kevin Martin, MD, professor of medicine and director of the division of nephrology at Saint Louis University School of Medicine, about the challenges of managing hyperphosphatemia, prevention measures to recommend to patients at high risk for developing the condition, unmet needs in hyperphosphatemia management and more.

  Healio spoke with Kevin Martin, MD, professor of medicine and director of the division of nephrology at Saint Louis University School of Medicine, about the challenges of managing hyperphosphatemia, prevention measures to recommend to patients at high risk for developing the condition, unmet needs in hyperphosphatemia management and more.

  Healio spoke with Kevin Martin, MD, professor of medicine and director of the division of nephrology at Saint Louis University School of Medicine, about the challenges of managing hyperphosphatemia, prevention measures to recommend to patients at high risk for developing the condition, unmet needs in hyperphosphatemia management and more.

VANCOUVER, British Columbia — Adult patients with inflammatory bowel disease are at increased risk for respiratory syncytial virus infection and hospitalization, especially those with comorbidities, according to data presented here.

Upacicalcet, an injectable calcimimetic, may be an effective and safe therapy for adults with secondary hyperparathyroidism on hemodialysis, according to a recently published study.

The FDA has set a user fee goal date of March 27, 2024, for review of the oral hypoxia-inducible factor prolyl hydroxylase inhibitor vadadustat for the treatment of anemia in adults on dialysis.

A structured exercise intervention slowed kidney function decline in older adults and higher activity was associated with overall health improvements, research shows.

In patients with chronic kidney disease, high diastolic blood pressure did not increase risk for adverse kidney or cardiovascular events if systolic BP is under control, according to a study published in Kidney Medicine.

Novo Nordisk has ended a clinical trial evaluating the impact of semaglutide on kidney function after the results from an interim analysis met certain pre-specified criteria, according to a company press release. To protect the integrity of the trial, Novo Nordisk will remain blinded to the results until the trial is completed, likely during the first half of 2024, according to the release.